Epidermolysis bullosa (EB) is a heterogeneous group of rare, inherited skin diseases characterized by recurrent painful skin lesions, often precipitated by minor trauma resulting in dermal-epidermal separation or split. Treatment for this family of 23 genetic skin disorders is mainly supportive as there is as yet no radical and effective therapy for them. The objective of this study was to evaluate the acceptability, tolerance and efficacy of a novel contact layer dressing* in the management of epidermolysis bullosa (EB) skin lesions. Methods: This was an open-label clinical trial involving 20 patients (eleven adults and nine children) suffering from EB simplex or dystrophic EB. Patients were selected from the register of EB patients at the investigating center and included subjects who presented with at least one skin lesion. Lesions were treated with the study dressing for a maximum of four weeks. All dressing changes, wound parameters, pain and effect on quality of life were recorded. Results: All the patients completed the trial. Nineteen out of 20 wounds healed within 8.7 +/- 8.5 days. Overall, 11 patients (55%) considered that their quality of life had improved following use of the dressing, which was also reported to 'very easy' or 'easy' to remove at most dressing changes. Nineteen out of 20 patients stated that they would use the study dressing to manage their lesions in the future. Conclusion: This study confirmed the very good acceptability and efficacy of a new contact layer dressing * in the treatment of skin lesions in patients with EB. * Restore Contact Layer with Triact Technology, Hollister Wound Care, Libertyville, IL. Supported in part by Hollister Wound Care, LLC